156 related articles for article (PubMed ID: 12540801)
1. Octreotide treatment of hepatocellular carcinoma.
Kouroumalis E; Samonakis D; Skordilis P
Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
[No Abstract] [Full Text] [Related]
2. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
Allgaier HP; Becker G; Blum HE
Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
[No Abstract] [Full Text] [Related]
3. Octreotide and hepatocellular carcinoma.
Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
[No Abstract] [Full Text] [Related]
4. [Somatostatin analogue (octreotide)].
Sano K; Makuuchi M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
[No Abstract] [Full Text] [Related]
5. Octreotide in hepatocellular carcinoma.
Shouval D
Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
[No Abstract] [Full Text] [Related]
6. The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma.
Borbath I; Horsmans Y
Hepatology; 2003 Feb; 37(2):477-8; author reply 478. PubMed ID: 12575712
[No Abstract] [Full Text] [Related]
7. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
8. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
[No Abstract] [Full Text] [Related]
9. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
10. Complete regression of advanced HCC with long acting octreotide.
Siveke JT; Herberhold C; Folwaczny C
Gut; 2003 Oct; 52(10):1531. PubMed ID: 12970151
[No Abstract] [Full Text] [Related]
11. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight.
Samonakis DN; Christodoulakis N; Kouroumalis EA
J Clin Gastroenterol; 2006 Jan; 40(1):86-7. PubMed ID: 16340641
[No Abstract] [Full Text] [Related]
12. [Treatment of hepatocellular carcinoma with tamoxifen].
Raoul JL
Gastroenterol Clin Biol; 1996 Mar; 20(2):221-2. PubMed ID: 8761695
[No Abstract] [Full Text] [Related]
13. Somatostatin and hepatocellular carcinoma.
Kapadia CR
Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
[No Abstract] [Full Text] [Related]
14. Octreotide inhibits the growth and development of three types of experimental liver metastasis.
Frizelle FA
Br J Surg; 1995 Nov; 82(11):1577. PubMed ID: 8535822
[No Abstract] [Full Text] [Related]
15. [Tamoxifen and hepatocellular carcinoma: verdict after enthusiasm...].
Barbare JC
Gastroenterol Clin Biol; 1996; 20(6-7):609-10. PubMed ID: 8881581
[No Abstract] [Full Text] [Related]
16. Megestrol treatment in patients with hepatocellular carcinoma.
Farinati F; Gianni S; De Giorgio M; Fiorentini S
Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452
[No Abstract] [Full Text] [Related]
17. The role of somatostatin analogs in the management of hepatocellular carcinoma.
D'Agostino L; Manguso F; Pivonello R; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
[No Abstract] [Full Text] [Related]
18. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
Chow PK
Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
[No Abstract] [Full Text] [Related]
19. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
[TBL] [Abstract][Full Text] [Related]
20. [Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].
Kreysel C; Porschen R
Z Gastroenterol; 1998 Jul; 36(7):605-7. PubMed ID: 9738309
[No Abstract] [Full Text] [Related]
[Next] [New Search]